GLENMARK Intraday Analysis...

GLENMARK Share Price

Open 876.55 Change Price %
High 876.60 1 Day -14.55 -1.66
Low 859.30 1 Week -44.70 -4.93
Close 861.85 1 Month -79.35 -8.43
Volume 390408 1 Year -117.40 -11.99
52 Week High 994.00
52 Week Low 671.10
GLENMARK Important Levels
Resistance 2 877.89
Resistance 1 871.28
Pivot 865.92
Support 1 852.42
Support 2 845.81
NSE INDIA Most Active Stocks
HCC 40.55 -0.86%
HCC 40.55 -0.86%
VISESHINFO 0.30 0.00%
SBIN 254.10 -0.61%
ASHOKLEY 74.70 -3.68%
IDFCBANK 66.85 -1.69%
ADANIPOWER 29.15 0.17%
UNITECH 4.75 -5.00%
JPASSOCIAT 7.55 -2.58%
IDEA 73.45 0.89%
More..
NSE INDIA Top Gainers Stocks
RASOYPR 0.20 33.33%
SPYL 2.00 17.65%
AUSOMENT 26.25 16.41%
AURIONPRO 116.40 15.48%
SHYAMTEL 33.30 15.22%
PARRYSUGAR 50.75 13.79%
NICCO 0.55 10.00%
TFL 11.00 10.00%
LYCOS 8.95 9.82%
DATAMATICS 88.10 9.71%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.15 -25.00%
SRGINFOTEC 0.25 -16.67%
RAJRAYON 0.25 -16.67%
DBL 224.55 -11.61%
DBL 224.55 -11.61%
DBL 224.55 -11.61%
BLUECHIP 0.40 -11.11%
REIAGROLTD 0.45 -10.00%
NAKODA 0.45 -10.00%
REISIXTEN 0.55 -8.33%
More..

Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

GLENMARK Technical Analysis 2
As on 2nd Dec 2016 GLENMARK Share Price closed @ 861.85 and we RECOMMEND Buy for LONG-TERM with Stoploss of 839.84 & Strong Sell for SHORT-TERM with Stoploss of 910.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLENMARK Target for December
1st Target up-side 977.52
2nd Target up-side 1048.95
3rd Target up-side 1120.38
1st Target down-side 773.69
2nd Target down-side 702.25
3rd Target down-side 630.82
GLENMARK Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 40.76 Sideways
MFI (14) MFI is 31.65 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 815.56
10 Day Avg Volume Traded -28.31 % Less then 10 Day Average Volume
GLENMARK Other Details
Segment EQ
Market Capital 68178259968.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.glenmarkpharma.com
GLENMARK Address
GLENMARK
Glenmark House
B D S Marg
Mumbai, 400099
India
Phone: 91 22 4018 9999
Fax: 91 22 4018 9990
GLENMARK Latest News
Interactive Technical Analysis Chart Glenmark Pharmaceuticals Limited ( GLENMARK NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Glenmark Pharmaceuticals Limited
GLENMARK Business Profile
Glenmark Pharmaceuticals (GPL) is engaged in the research and development, manufacturing and marketing of branded formulations in India and abroad. The company is headquartered at Mumbai and was incorporated in the year 1977 by Gracias Saldanha. Its business segments include India API, exports formulations and API NCE research. The company is present in over 80 countries across the globe, with some of its subsidiaries and representative offices in the United States, the United Kingdom, Switzerland, Brazil, South Africa, Nigeria, Russia, Philippines and Malaysia. It has been involved in new drug discoveries such as new molecules for asthma, obesity and diabetes segments. Glenmark has been involved in API business. Glenmark conducts its operations through its manufacturing plants including Baddi, Goa, Nasik and Sao Paulo, Brazil for formulations and Ankleshwar, Kurkumbh and Solapur for API. Glenmark Pharmaceuticals` research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar, India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. The company is further researching PDE-4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas include diabetes segment in which the company has a DPP-IV target, GRC 8200, in Phase I clinical trials. For the last five years the company has increased its growth through investment in dedicated research and development, including cutting-edge New Chemical Technology (NCE) research. The company currently ranks among the top 20 Indian pharmaceutical firms. The current market capitalization stands at Rs 13,855.67 crore. The company has reported a consolidated sales of Rs 1463.38 crore and a Net Profit of Rs 157.3 crore for the quarter ended September 2013. The company management includes Glenn Saldanha - Chairman & Managing Director, Rajesh V Desai - Executive Director & CFO, Cherylann Pinto - Director - Corporate Affairs, D R Mehta - Non Executive Director, Bernard Munos - Non Executive Director, J F Ribeiro - Non Executive Director, Brian W Tempest - Non Executive Director, Sridhar Gorthi - Non Executive Director, Hocine Sidi Said - Non Executive Director, N B Desai - Non Executive Director. The Registered office is at B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai,Maharashtra - 400026 and corporate office is at Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E, Mumbai - 400099 in MAHARASHTRA.